Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (271-280 of 376) with videos related to

Pageof 38
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging TherapiesMark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
Dermatology and Therapy|May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
The Journal of Investigative Dermatology|October 17, 2014
Proceedings of the Inaugural Pediatric Dermatology Research Alliance (PeDRA) conferenceDawn H Siegel, Keith A Choate, Beth A Drolet, et al.
Journal of the American Academy of Dermatology|February 5, 2026
Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Dermatology and Therapy|September 26, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic DermatitisMichael J Cork, Diamant Thaçi, Lawrence F Eichenfield, et al.
Dermatology and Therapy|May 11, 2022
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records DatasetLawrence F Eichenfield, April Armstrong, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Pageof 38

Showing results (271-280 of 376) with videos related to

Sort By:
Pageof 38
The Journal of Allergy and Clinical Immunology. in Practice|October 4, 2017
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging TherapiesMark Boguniewicz, Andrew F Alexis, Lisa A Beck, et al.
Journal of Drugs in Dermatology : JDD|February 23, 2019
Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in PracticeMark Lebwohl, Andrew F. Alexis, Lisa A. Beck, et al.
Dermatology and Therapy|May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
The Journal of Investigative Dermatology|October 17, 2014
Proceedings of the Inaugural Pediatric Dermatology Research Alliance (PeDRA) conferenceDawn H Siegel, Keith A Choate, Beth A Drolet, et al.
Journal of the American Academy of Dermatology|February 5, 2026
Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results From the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.
Dermatology and Therapy|September 26, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic DermatitisMichael J Cork, Diamant Thaçi, Lawrence F Eichenfield, et al.
Dermatology and Therapy|May 11, 2022
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records DatasetLawrence F Eichenfield, April Armstrong, Emma Guttman-Yassky, et al.
Journal of the American Academy of Dermatology|February 18, 2026
The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective trialJonathan I Silverberg, Lawrence F Eichenfield, April W Armstrong, et al.
Journal of the American Academy of Dermatology|August 12, 2015
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyIan Landells, Colleen Marano, Ming-Chun Hsu, et al.
Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.
Pageof 38